Development of oral immunomodulatory agents in the management of multiple sclerosis

Development of oral immunomodulatory agents in the management of multiple sclerosis

Item
http://www.wikidata.org/entity/Q28388704
Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapyGlycoengineering of interferon-β 1a improves its biophysical and pharmacokinetic propertiesThe effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.Dimethyl fumarate inhibits osteoclasts via attenuation of reactive oxygen species signalling by augmented antioxidation.Mycophenolate mofetil improves neurological function and alters blood T-lymphocyte subsets in rats with experimental autoimmune encephalomyelitis.Chances and challenges of retinoid X receptor gamma targeting for regenerative multiple sclerosis treatment.Immunomodulatory Effects of Kuseonwangdogo-Based Mixed Herbal Formula Extracts on a Cyclophosphamide-Induced Immunosuppression Mouse Model.Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model.
P2860

Development of oral immunomodulatory agents in the management of multiple sclerosis

Item
http://www.wikidata.org/entity/Q28388704
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Development of oral immunomodulatory agents in the management of multiple sclerosis
@ast
Development of oral immunomodulatory agents in the management of multiple sclerosis
@en
Development of oral immunomodulatory agents in the management of multiple sclerosis
@nl
type
label
Development of oral immunomodulatory agents in the management of multiple sclerosis
@ast
Development of oral immunomodulatory agents in the management of multiple sclerosis
@en
Development of oral immunomodulatory agents in the management of multiple sclerosis
@nl
prefLabel
Development of oral immunomodulatory agents in the management of multiple sclerosis
@ast
Development of oral immunomodulatory agents in the management of multiple sclerosis
@en
Development of oral immunomodulatory agents in the management of multiple sclerosis
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Development of oral immunomodulatory agents in the management of multiple sclerosis
@en
P2093
P2860
P304
P31
P356
P407
P478
P50
P577
P698
P921
P932